These authors concluded that the enhanced cell surface shedding of FGFR2 carried out by the increased catalytic activity of ADAM15B was involved in the progression of breast cancer and suggested that inhibitors of ADAM15 or of the ADAM15B/Src interaction might be effective to treat patients with breast cancer with dysregulated ADAM15. Here, SRC is linked to breast carcinoma.